Physician profile
Michael A Rothbaum
NPI 1154387611
$3,023.45
in general payments reported to CMS, 2019-2025
28 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.68 · 2020: $344 · 2021: $642 · 2022: $358 · 2023: $626 · 2024: $453 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $377.58 | 2019-2025 | Argos, Rocklatan, Clareon |
| Regeneron Healthcare Solutions, INC. | $358.15 | 2021-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $321.21 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Allergan, INC. | $311.24 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $186.39 | 2019-2025 | Cequa |
| Apellis Pharmaceuticals, INC. | $164.34 | 2023-2025 | Syfovre |
| Oyster Point Pharma, INC. | $153.21 | 2022-2024 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $128.93 | 2021-2022 | |
| Horizon Therapeutics Plc | $120.14 | 2021-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.84 | 2020-2021 | |
| Lensar, INC. | $114.34 | 2021 | |
| Genentech USA, INC. | $77.65 | 2022-2024 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $63.94 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $58.95 | 2022-2025 | Vyzulta, Alrex, Prolensa |
| Dompe US, INC. | $55.42 | 2025 | Oxervate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $54.79 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $53.35 | 2020-2021 | |
| Ivantis, INC | $48.51 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $44.63 | 2024-2025 | Tecnis Simplicity, Baerveldt Glaucoma Implant (250) |
| Omeros Corporation | $32.28 | 2019 | |
| Quidel Corporation | $32.24 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $30.85 | 2024 | Xdemvy |
| Ani Pharmaceuticals, INC. | $26.09 | 2025 | Purified Cortrophin Gel |
| Ocular Therapeutix, INC. | $20.08 | 2023 | Dextenza |
| Astellas Pharma US INC | $19.56 | 2024 | Izervay |
| Carl Zeiss Meditec USA, INC. | $19.02 | 2023 | Iolmaster 700 |
| Amgen INC. | $18.74 | 2025 | Tepezza |
| Shire North American Group INC | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rothbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.